PMID- 10802800 OWN - NLM STAT- MEDLINE DCOM- 20000530 LR - 20190514 IS - 0028-3878 (Print) IS - 0028-3878 (Linking) VI - 54 IP - 9 DP - 2000 May 9 TI - Interaction between HLA-DR2 and abnormal brain MRI in optic neuritis and early MS. Optic Neuritis Study Group. PG - 1859-61 AB - The association of the human leukocyte antigen (HLA)-DR2 allele with brain MRI signal abnormalities and with the development of MS was assessed in 178 patients enrolled in the Optic Neuritis Treatment Trial. HLA haplotype DR2 was present in 85 (48%) of the 178 patients. Its presence was associated with increased odds of probable or definite MS at 5 years (odds ratio, 1.92; 95% confidence interval, 1.01 to 3.67; p = 0.04). The association was most apparent among patients with signal abnormalities on baseline brain MRI. FAU - Hauser, S L AU - Hauser SL AD - Department of Neurology, University of California, San Francisco, CA, USA. FAU - Oksenberg, J R AU - Oksenberg JR FAU - Lincoln, R AU - Lincoln R FAU - Garovoy, J AU - Garovoy J FAU - Beck, R W AU - Beck RW FAU - Cole, S R AU - Cole SR FAU - Moke, P S AU - Moke PS FAU - Kip, K E AU - Kip KE FAU - Gal, R L AU - Gal RL FAU - Long, D T AU - Long DT LA - eng GR - EY05435/EY/NEI NIH HHS/United States GR - NS26799/NS/NINDS NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Neurology JT - Neurology JID - 0401060 RN - 0 (HLA-DR2 Antigen) RN - VB0R961HZT (Prednisone) RN - X4W7ZR7023 (Methylprednisolone) SB - IM MH - Administration, Oral MH - Adult MH - Alleles MH - Brain/drug effects/*pathology MH - Drug Therapy, Combination MH - Female MH - HLA-DR2 Antigen/*genetics MH - Haplotypes/genetics MH - Humans MH - Infusions, Intravenous MH - *Magnetic Resonance Imaging MH - Male MH - Methylprednisolone/administration & dosage/adverse effects MH - Middle Aged MH - Multiple Sclerosis/*diagnosis/drug therapy/genetics MH - Optic Neuritis/*diagnosis/drug therapy/genetics MH - Prednisone/administration & dosage/adverse effects EDAT- 2000/05/10 09:00 MHDA- 2000/06/03 09:00 CRDT- 2000/05/10 09:00 PHST- 2000/05/10 09:00 [pubmed] PHST- 2000/06/03 09:00 [medline] PHST- 2000/05/10 09:00 [entrez] AID - 10.1212/wnl.54.9.1859 [doi] PST - ppublish SO - Neurology. 2000 May 9;54(9):1859-61. doi: 10.1212/wnl.54.9.1859.